Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6

Editas Medicine, Inc.

As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.
Mean total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6 (n=18).
Mean HbF percentage reached 48.1% at Month 6; F-cells >90% from Month 4; MCH-F above anti-sickling threshold.
All evaluable patients engrafted; median time to neutrophil engraftment 23 days, platelet 25 days.
Two SAEs possibly related to reni-cel reported; safety consistent with myeloablative conditioning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.